Director at Tyra Biosciences (NASDAQ: TYRA) awarded stock options

Rhea-AI Filing Summary

Tyra Biosciences director Robert J. More received a grant of stock options covering 13,160 shares of common stock at an exercise price of $32.68 per share. The options expire on May 27, 2036 and vest in 12 equal monthly installments after May 28, 2026. Any remaining unvested portion will fully vest at the next annual stockholder meeting if it occurs before the first anniversary of the grant date, subject to his continuous service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MORE ROBERT J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,160	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 13,160 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 13,160 shares Exercise price: $32.68 per share Expiration date: May 27, 2036 +2 more

5 metrics

Option grant size 13,160 shares Stock options granted to director Robert J. More

Exercise price $32.68 per share Stock option exercise price for the 13,160-share grant

Expiration date May 27, 2036 Option expiration for the director grant

Vesting schedule 1/12 monthly Vests monthly following May 28, 2026 over 12 months

Shares after grant 13,160 derivative securities Total stock options held after this transaction

Key Terms

Non-Employee Director Compensation Program, stock option, vest, annual meeting of the Issuer's stockholders

4 terms

Non-Employee Director Compensation Program financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

stock option financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest financial

"1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of the Issuer's stockholders financial

"In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORE ROBERT J

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.68	05/28/2026		A		13,160		(1)	05/27/2036	Common Stock	13,160	$0	13,160	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Ali D. Fawaz, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tyra Biosciences (TYRA) report in this Form 4 filing?

Tyra Biosciences reported a stock option grant to director Robert J. More. He received options for 13,160 shares of common stock as part of the company’s non-employee director compensation program.

How many Tyra Biosciences (TYRA) shares are covered by the new options?

The new stock option grant covers 13,160 shares of Tyra Biosciences common stock. These options give the director the right to buy that number of shares if he chooses to exercise them in the future.

What is the exercise price of the Tyra Biosciences (TYRA) stock options?

The stock options have an exercise price of $32.68 per share. This means the director can purchase Tyra Biosciences common stock at $32.68 per share once the options vest and before they expire.

When do the Tyra Biosciences (TYRA) options granted to Robert J. More vest?

The options vest in 12 equal monthly installments after May 28, 2026. If the next annual stockholder meeting occurs before the first anniversary of the grant date, any remaining unvested options vest on that meeting date, subject to continuous service.

When do the newly granted Tyra Biosciences (TYRA) stock options expire?

The stock options granted to director Robert J. More expire on May 27, 2036. He must exercise any vested options before that expiration date if he wants to purchase the underlying Tyra Biosciences shares.

Is this Tyra Biosciences (TYRA) Form 4 transaction an open-market purchase or sale?

No, this Form 4 shows a grant of stock options as compensation, not an open-market trade. The director did not buy or sell shares on the market; he received options under the non-employee director compensation program.